**Core tip:** The treatment of advanced gastric cancer in the West continues to evolve and advance. Surgery-related outcomes continue to improve and have included the addition of minimally invasive surgery techniques. The use of chemotherapy to improve long-term survival outcomes has been demonstrated in randomized-controlled trials, though the best regimen to use continues to be investigated. Chemoradiation has also been shown to improve outcomes, though the timing, sequence, and patient-population for optimal benefit has yet to be determined. Targeted-therapies and intraperitoneal chemotherapy may also play a role in the treatment of patients with advanced gastric cancer.

INTRODUCTION
============

Gastric cancer is the fifth most frequently diagnosed cancer and is the third leading cause of cancer death worldwide\[[@B1]\]. However, nearly 50% of these cases are diagnosed in Eastern Asia with over 70% of gastric cancer occurring outside of the United States\[[@B2]\]. Overall, the incidence of gastric cancer in the United States has been declining while overall survival (OS) rates have been steadily increasing\[[@B3]\]. Non-cardia gastric cancers have seen a decrease in incidence which has been attributed to changes in diet and treatment of chronic *Helicobactor pylori* infections which account for nearly 90% of new non-cardia gastric cancer cases\[[@B2],[@B4]\]. Gastric cancers of the cardia, on the other hand, have seen an increase in incidence, and are associated with factors like obesity, Epstein-Barr virus and gastroesophageal reflux disease\[[@B1],[@B3],[@B5]\]. Additionally, recent studies suggest that while the incidence of gastric cancer in the United States is declining for those aged 40-84, the incidence of gastric cancer in the young is increasing, particularly in young Hispanic males\[[@B4]\]. Young gastric cancer patients are more likely to present with aggressive histologic factors such as poor differentiation, signet ring cells, diffuse histology, and linitis plastica, as well as more advanced nodal metastasis at presentation\[[@B6],[@B7]\].

Outcomes for patients with advanced gastric cancer greatly depend on whether they have resectable disease. Patients with unresectable advanced disease have very poor outcomes with median survivals of just 10-18 mo\[[@B8],[@B9]\]. Long-term survival for patients with resected advanced gastric cancer has improved as medical and surgical therapies have advanced. OS at 5 years after a curative resection was once just 19% in the 1980's but has now improved to 40%-70%\[[@B10]-[@B12]\]. Unfortunately, nearly half of patients with an R0 resection have a recurrence and median survival after a recurrence is just 6 mo\[[@B13]\]. These outcomes show that there remains room for improvement in the treatment of advanced gastric cancer. Here, we review the advancements and challenges of treating advanced gastric cancer in the West.

SURGERY
=======

Surgery for gastric cancer is associated with significant morbidity and mortality. A study of more than 700 American College of Surgeons (ACS) approved cancer programs in the United States during the 1980s reported a 30-d mortality of 7%\[[@B12]\]. With improvements in surgical technique, instruments, anesthesia, and peri-operative care, the morbidity and mortality associated with gastrectomy has improved in the United States. A 2005-2010 ACS NSQIP study looking at outcomes in patients undergoing total or partial gastrectomies for gastric cancer found that 24% experienced a major morbidity and the 30-d mortality was 4%\[[@B14]\]. If additional procedures were required (*e.g*., splenectomy or pancreatectomy), major morbidity increased to nearly 30%\[[@B14]\]. A second NSQIP study in the same time period looking at total gastrectomies alone found similar results with 36% of patients experiencing a complication and a 30-day mortality of 5%\[[@B15]\]. Additionally, the 30-day mortality increased to 13% in patients who underwent a pancreatectomy in addition to a total gastrectomy\[[@B15]\].

The benefit of multivisceral resection has been debated given the higher morbidity and mortality associated with these procedures, which is generally reported around 3% and 30%-40% respectively\[[@B16]-[@B18]\]. The number of patients undergoing curative-intent resection who require a multivisceral resection is anywhere from 19%-66%\[[@B16],[@B17]\]. A Canadian study found that combining systemic therapy with multivisceral resections can result in a high rate of margin negative resection\[[@B19]\]. The 5-year survival was 34% and there were few locoregional recurrences with an acceptable morbidity and mortality\[[@B19]\]. A systematic review reported similar conclusions in that multivisceral resections may be helpful in achieving an R0 resection margin\[[@B20]\]. The United States Gastric Cancer Collaborative found that patients who underwent a multivisceral resection without a pancreatectomy had higher post-operative morbidity than those who underwent a gastrectomy alone but there was no change in mortality, while a multivisceral resection with a pancreatectomy was an independent predictor of worse OS\[[@B17]\]. This data would suggest that in appropriately selected patients with locally advanced gastric cancer, a multivisceral resection can be performed at high volume centers with a high rate of negative margins and an acceptable morbidity and mortality. The inclusion of pancreatectomy is an independent predictor of poor outcome and must be used selectively.

The stomach has a multidirectional and complex network of regional lymphatic vessels and nodes\[[@B21]\]. Gastric cancer has a high tendency to metastasize to these regional lymph nodes and their involvement is an important prognostic factor\[[@B22]\]. As such, lymph node retrieval is an important aspect of staging for gastric cancer and has implications in adjuvant treatment recommendations (Table [1](#T1){ref-type="table"})\[[@B22]-[@B24]\]. The final publication of the Dutch trial reported lower locoregional recurrence and gastric cancer-related death in patients undergoing a D2 lymphadenectomy compared to a D1 lymphadenectomy\[[@B25]\]. Similarly, an Italian trial demonstrated a survival benefit for patients with positive nodes treated with D2 gastrectomy without splenectomy and pancreatectomy\[[@B26]\]. As such, a pancreas and spleen preserving, or modified D2 lymphadenectomy, is now the standard of care at most academic institutions throughout the United States.

###### 

Surgery trials

  **Trial name**                                                                                **Country**   **Status**   **Years**   **Factors**                                                                                               **Outcome**
  --------------------------------------------------------------------------------------------- ------------- ------------ ----------- --------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  DGCT Trial                                                                                    Netherlands   Complete     1989-1993   Randomization to D1 or D2 lymphadenectomy                                                                 Increased morbidity and mortality in D2 group
                                                                                                                                                                                                                                                 
  Decreased gastric cancer-related deaths and locoregional recurrences after D2 resection                                                                                                                                                        
  IGCSG-R01                                                                                     Italy         Complete     1998-2006   Randomization to D1 or D2 lymphadenectomy                                                                 No difference in morbidity and mortality
                                                                                                                                                                                                                                                 
  Improved 5-yr survival in subgroup analysis of patients with positive LN after D2 resection                                                                                                                                                    
  KLASS-01[1](#T1FN1){ref-type="table-fn"}                                                      Korea         Complete     2006-2010   Randomization to open distal gastrectomy or laparoscopic distal gastrectomy                               Decreased wound complication rate in laparoscopic group with no difference in morbidity or mortality
  KLASS-02[2](#T1FN2){ref-type="table-fn"}                                                      Korea         Complete     2011-2015   Randomization to open or laparoscopic gastrectomy and D2 lymph node resection                             Decreased complication rates and pain scores with shorter hospital stays in laparoscopic resections
  JCOG 0703[1](#T1FN1){ref-type="table-fn"}                                                     Japan         Complete     2007-2008   Prospective study with patients undergoing laparoscopic distal gastrectomy with D1 lymph node resection   Laparoscopic surgery was safe with lower than expected rates of anastomotic leaks and pancreatic fistulas

Clinical stage I gastric cancers only;

Locally advanced gastric cancers only. DGCT: Dutch Gastric Cancer Group Trial; IGCSG: Italian Gastric Cancer Study Group; LN: Lymph node; KLASS: Korean Laparoscopic Surgical Society; JCOG: Japan Clinical Oncology Group.

Similarly, the total number of lymph nodes removed during gastrectomy is an independent predictor of survival, with an increasing number of excised lymph nodes being associated with a decreased risk of death\[[@B27]\]. As such, the recently, published American Joint Committee on Cancer 8^th^ edition tumor-node-metastasis-staging guidelines recommend a minimum of 16 lymph nodes be assessed in gastric cancer with 30 or more lymph nodes being desirable\[[@B28]\]. Despite this, most patients in the west do not receive an adequate lymphadenectomy. A recent NCDB study found that only 23% of patients had evaluation of the recommended 15 lymph nodes\[[@B29]\]. That same study showed that patients who were treated in National Cancer Institute-designated centers or high-volume centers were more likely to have the recommended lymph node retrieval\[[@B29]\]. A Surveillance, Epidemiology and End Results (SEER) analysis found that from 2004-2010, only 42% of patients had at least 15 lymph nodes evaluated after surgery, and while being treated at a cancer program increased the odds of having 15 nodes removed, improved survival was significant with removal of 15 or more lymph nodes regardless of treatment location\[[@B30]\]. The ability to obtain 15 lymph nodes can be difficult if a D1 resection, rather than a D2, is utilized\[[@B31]\]. Recently, the National Comprehensive Cancer Network (NCCN) has recommended performing a D2 lymphadenectomy with the goal of obtaining at least 15 lymph nodes while avoiding a splenectomy\[[@B32]\].

There has been a slow increase in minimally invasive surgery for gastric cancer over time. The first description of a laparoscopic gastrectomy was in 1994 from a group in Japan\[[@B33]\]. In the United States, a SEER analysis from 2008-2013 showed that only 8% of gastrectomies were performed laparoscopically and only 2% were performed robotically\[[@B34]\]. There was also no significant increase in the last three years of this analysis indicating that the use of laparoscopic surgery for gastric cancer has not continued to increase\[[@B34]\]. This is in contrast to a nearly 26% utilization by Eastern countries\[[@B35]\]. Data from the NCDB showed that only 13% of cases were done laparoscopically between 1998-2011 with a conversion from laparoscopic to open in nearly 24% of cases\[[@B36]\]. Another study from the NCDB showed that between 2010 and 2012, there was an increase in the use of minimally invasive techniques with 4% being performed robotically and 23% undergoing laparoscopic gastrectomies\[[@B37]\]. This study also found that open gastrectomies are decreasing overall, with a rise in both laparoscopic and robotic gastrectomies\[[@B37]\].

Two prospective trials, KLASS-01 and JCOG 0703, as well as several retrospective studies support the safety and oncologic feasibility of laparoscopic surgery for early gastric cancer (Table [1](#T1){ref-type="table"})\[[@B38],[@B39]\]. Fewer studies have addressed laparoscopy in advanced gastric cancer. The KLASS-02 trial randomized patients with locally advanced gastric cancer to either laparoscopic or open distal gastrectomy\[[@B40]\]. Short term outcomes from this trial were recently published and demonstrated benefits in terms of lower complication rates, lower pain score, earlier return of bowel function, and shorter hospital length of stays compared to open surgery\[[@B41]\]. A primary concern regarding minimally invasive surgery for advanced gastric cancer is whether adequate lymph node retrieval could be achieved. A study from the United States Gastric Cancer Collaborative showed similar rates of lymph nodes retrieved between a minimally invasive cohort and an open cohort, both overall and after propensity matching\[[@B42]\]. From an outcomes standpoint, a NSQIP analysis of patients undergoing laparoscopic *vs*. open gastrectomies showed fewer complications for patients undergoing laparoscopic gastrectomies with no difference in mortality\[[@B43]\]. As western surgeons become more experienced and minimally invasive technology improves (*e.g*., 3D visualization and robotic surgery), minimally invasive surgery will likely become safer and more oncologically sound for western patients with advanced gastric cancer.

CHEMOTHERAPY
============

The role of systemic chemotherapy for the treatment of advanced gastric cancer has evolved over time as we continue to search for optimal therapies and treatment sequencing that will positively influence outcomes (Table [2](#T2){ref-type="table"}). The MAGIC trial was the first large prospective trial that observed improved outcomes in patients who received perioperative chemotherapy\[[@B44]\]. The agents used in this study were epirubicin, cisplatin, and 5-fluorouracil (ECF). This study showed improved outcomes even with only 42% of patients receiving the full six cycles of chemotherapy, with many patients being unable to complete their post-operative cycles. Patients who received pre-operative chemotherapy demonstrated significant down-staging as evidenced by smaller tumors and less lymph node involvement, but most importantly, had significantly better overall and progression-free survival\[[@B44]\]. Perioperative chemotherapy has since become standard of care for patients with non-metastatic stage II or higher gastric cancers. The use of perioperative chemotherapy in the United States has increased overtime since the MAGIC trial. In the year 2003, just 25% of patients were receiving neoadjuvant chemotherapy while in 2012 the rate increased to over 45%\[[@B45]\]. A later trial, the ACCORD 07, was a phase III randomized trial that again showed a significant improvement in overall and progression free survival in patients that underwent perioperative chemotherapy and surgery compared to those that underwent surgery alone\[[@B46]\]. This trial used cisplatin and 5-fluorouracil without epirubicin and OS were similar between the MAGIC and the ACCORD 07 trial with 5-year survivals around 30%\[[@B44],[@B46]\].

###### 

Chemotherapy trials

  **Trial name**                     **Country**                                    **Status**                                                **Years**   **Groups**            **Chemotherapy regimens**                                               **Outcome**
  ---------------------------------- ---------------------------------------------- --------------------------------------------------------- ----------- --------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------
  MAGIC                              UK                                             Complete                                                  1994-2002   Surgery alone         \-                                                                      Smaller tumors in chemo group (3 cm *vs* 5 cm)
  Surgery with perioperative chemo   Epirubicin, cisplatin, 5-FU (ECF)              Better PFS and OS in chemo group (5-yr OS 36% *vs* 23%)                                                                                                             
  ACCORD 07                          France                                         Complete                                                  1995-2003   Surgery alone         \-                                                                      Improved curative resection rates with chemo (84% *vs* 73%)
  Surgery with perioperative chemo   Cisplatin and 5-FU                             Better DFS and OS in chemo group (5-yr OS 38% *vs* 24%)                                                                                                             
  AIO-FLOT4 (Phase II)               Germany                                        Complete                                                  2010-2012   Neoadjuvant ECF/ECX   Epirubicin and cisplatin with either 5-FU (ECF) or capecitabine (ECX)   Improved pathological complete regression in FLOT *vs* ECF/ECX
  Neoadjuvant FLOT                   Docetaxel, oxaliplatin, 5-FU with leucovorin                                                                                                                                                                       
  AIO-FLOT4 (Phase III)              Germany                                        Complete                                                  2010-2015   Neoadjuvant ECF/ECX   Epirubicin and cisplatin with either 5-FU (ECF) or capecitabine (ECX)   Improved OS in FLOT group with no increase in toxicities
  Neoadjuvant FLOT                   Docetaxel, oxaliplatin, 5-FU with leucovorin                                                                                                                                                                       

MAGIC: Medical Research Council Adjuvant Gastric Infusional Chemotherapy; UK: United Kingdom; 5-FU: 5-fluorouracil; PFS: Progression-free survival; OS: Overall survival; DFS: Disease-free survival; ECF: Epirubicin, cisplatin, and 5-fluorouracil; ECX: Epirubicin, cisplatin, and capecitabine; FLOT: 5-fluorouracil, leuocovorin, oxaliplatin, and docetaxel.

Neoadjuvant chemotherapy has several potential benefits to adjuvant chemotherapy. First, pre-operative chemotherapy is consistently better tolerated than post-operative chemotherapy in multiple trials\[[@B44],[@B46]\]. Second, blood supply to the tumor is not disrupted by surgical resection and micrometastasis can be treated at the earliest possible time\[[@B47]\]. Down-staging or shrinkage of the tumor may lead to higher R0 resection rates, particularly in advanced gastric cancer, and it allows the assessment of response to therapy allowing postoperative therapy to be tailored to the individual response to pre-operative therapy\[[@B48]\]. Unfortunately, very few patients receiving pre-operative ECF are able to achieve a complete pathologic response following neoadjuvant chemotherapy\[[@B49]\]. Tumor regression on final surgical pathology has been reported to be an independent factor associated with improved survival in patients receiving neoadjuvant chemotherapy for a number of cancers, including gastric\[[@B50],[@B51]\]. In a phase II study where patients received epirubicin, cisplatin, and capecitabine (ECX), a complete pathologic response was found in just 6%\[[@B49]\]. This compares to a complete response rates as high as 17%-20% in phase II studies where docetaxel is part of the treatment regimen\[[@B52],[@B53]\].

The AIO-FLOT4 trial looked to compare the rates of pathological regression in patients who received neoadjuvant ECF/ECX *vs* the docetaxel-based regimen FLOT (5-fluorouracil, leuocovorin, oxaliplatin, and docetaxel)\[[@B54]\]. Results of this study showed a significant increase in complete regression with FLOT treatment when compared to ECF (16% *vs* 6%). Recent phase III results of the FLOT4 randomized trial showed improved median OS of 50 mo for patient receiving the FLOT regimen compared to 35 mo for those on ECF/ECX with similar toxicities between the two groups\[[@B55]\]. The current NCCN guidelines recommend perioperative FLOT as the preferred regimen for medically fit patients with oxaliplatin and a fluoropyrimidine without docetaxel to be used in patients with a poor performance status or significant medical comorbidities\[[@B32]\].

RADIATION
=========

The benefit of chemoradiation in patients with locally advanced gastric cancer has been controversial (Table [3](#T3){ref-type="table"}). In the early 2000s, the Intergroup 0116 Trial showed that patients who underwent post-operative chemoradiation radiation therapy with 5-fluorouracil and leucovorin after a complete resection had improved long-term outcomes compared to patients who underwent surgery alone\[[@B56]\]. These patients did not undergo perioperative chemotherapy and the median survival in the surgery plus chemoradiation group was 36 mo compared to 27 mo in the surgery alone group\[[@B56]\]. This trial was criticized for its low (10%) utilization of D2 lymphadenectomy suggesting that chemoradiation may compensate for inadequate surgery. In contrast, a large retrospective United States multi-institutional study in which patients had a median 18 lymph nodes removed showed that post-operative chemoradiation with 5-fluorouracil improved both overall and recurrence-free survival when compared to patients who received perioperative chemotherapy alone\[[@B57]\]. On subgroup analysis, patients with nodal disease (N1) and lymphovascular invasion derived the most benefit\[[@B57]\].

###### 

Radiation trials

  **Trial name**                               **Country**                                                 **Status**                                                                           **Years**   **Trial group(s)**         **Regimens**                                         **Outcome**
  -------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------ ----------- -------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------
  INT-0116                                     US                                                          Complete                                                                             1991-1998   Surgery alone              \-                                                   Improved DSF and OS in radiation group (median survival 36 mo *vs* 27 mo)
  Surgery + adjuvant CRT                       45 Gy with 5-FU and leucovorin                                                                                                                                                                                                               
  Ajani et al\[[@B60]\]                        US                                                          Complete                                                                             1999-2004   CRT                        45 Gy with 5-FU, leucovorin, and cisplatin           77% R0 resection rate
  26% complete pathologic response rate                                                                                                                                                                                                                                                     
  Martin-Romano et al\[[@B61]\]                Spain                                                       Complete                                                                             2004-2014   Neoadjuvant chemotherapy   Variable                                             Improved pathologic response and nodal regression in CRT group
  Neoadjuvant CRT                              Radiation: 45 Gy                                                                                                                                                                                                                             
  Chemo: Variable                                                                                                                                                                                                                                                                           
  CRITICS                                      Netherlands, Sweden, Denmark                                Complete                                                                             2007-2015   Perioperative chemo        Epirubicin, cisplatin or oxaliplatin, capecitabine   No difference in OS or DFS
  Neoadjuvant chemo and adjuvant CRT           Chemo: Epirubicin, cisplatin or oxaliplatin, capecitabine                                                                                                                                                                                    
  CRT: 45 Gy with capecitabine                                                                                                                                                                                                                                                              
  CRITICS-II (NCT02931890)                     Netherlands, Sweden, Denmark                                Ongoing                                                                              \-          Neoadjuvant chemo          Docetaxel, oxaliplatin, capecitabine                 \-
  Neoadjuvant chemo and CRT                    Chemo: Docetaxel, oxaliplatin, capecitabine                                                                                                                                                                                                  
  CRT: 45 Gy with paclitaxel and carboplatin                                                                                                                                                                                                                                                
  Neoadjuvant CRT                              45 Gy with paclitaxel and carboplatin                                                                                                                                                                                                        
  ARTIST                                       Korea                                                       Complete                                                                             2004-2008   Adjuvant chemo             Capecitabine and cisplatin                           No difference in DFS overall
  Adjuvant chemo and CRT                       Chemo: Capecitabine and cisplatin                           Superior DFS in radiation group on subgroup analysis of patients with positive LNs                                                                                               
  CRT: 45 Gy with capecitabine                                                                                                                                                                                                                                                              
  ARTIST-II (NCT01761461)                      Korea                                                       Ongoing                                                                              \-          Adjuvant chemo             S-1                                                  \-
  Adjuvant chemo                               S-1 and oxaliplatin                                                                                                                                                                                                                          
  Adjuvant chemo and CRT                       Chemo: S-1 and oxaliplatin                                                                                                                                                                                                                   
  CRT: 45Gy with S-1                                                                                                                                                                                                                                                                        
  TOPGEAR (ACTRN12609000035224)                Australia                                                   Ongoing                                                                              \-          Perioperative chemo        Epirubicin, cisplatin, 5-FU (ECF)                    \-
  Perioperative chemo with Neoadjuvant CRT     Chemo: Epirubicin, cisplatin, 5-FU (ECF)                                                                                                                                                                                                     
  CRT: 45 Gy with 5-FU                                                                                                                                                                                                                                                                      

INT: Intergroup; US: United States; CRT: Chemoradiation therapy; Gy: Gray; DFS: Disease-free survival; OS: Overall survival; 5-FU: 5-fluorouracil; CRITICS: Chemoradiotherapy after Induction chemotherapy In Cancer of the Stomach; chemo: Chemotherapy; LN: Lymph node; TOPGEAR: Trial Of Preoperative therapy for Gastric and Esophago-gastric junction Adenocarcinoma; ECF: Epirubicin, cisplatin, and 5-fluorouracil.

Neoadjuvant chemoradiation may improve R0 resection rate and achievement of pathological complete response (pCR) in advanced gastric cancer. A phase I multi-institutional single-arm trial in the US reported a 70% R0 resection rate and a 30% pCR rate with preoperative chemoradiation consisting of two 28-d cycles of induction fluorouracil, leucovorin, and cisplatin followed by fluorouracil-based chemoradiation therapy (CRT) to 45 Gy\[[@B58]\]. Pathological partial or complete response were associated with improved OS\[[@B59]\]. Similarly, another multi-institutional phase II trial in the United States reported a 77% R0 resection rate and 26% pCR rate following preoperative induction chemotherapy with two cycles of fluorouracil, leucovorin, and cisplatin followed by paclitaxel, fluorouracil, and concurrent 45 Gy radiotherapy\[[@B60]\]. A small retrospective series from Spain comparing neoadjuvant chemotherapy to neoadjuvant chemoradiation in resectable advanced gastric cancer demonstrated a significantly higher likelihood of achieving a Becker Ia-b response (58% *vs* 32%), a grade D nodal regression (30% *vs* 6%) and a favorable pathological response (23% *vs* 3%). Nodal, but not primary, response was associated with a longer 5-year progression-free and OS\[[@B61]\].

Whether chemoradiation offers a benefit in addition to or in place of chemotherapy is being actively prospectively investigated. The CRITICS trial randomized patients to perioperative chemotherapy *vs* pre-operative chemotherapy and post-operative CRT and was not able to show a survival difference between the two groups\[[@B11]\], however only 50% of patients received their intended post-operative treatment regimens in the CRITICS trial. The follow up CRITICS-II trial aims to optimize neoadjuvant therapy by comparing neoadjuvant chemotherapy alone, neoadjuvant chemotherapy followed by chemoradiation, and neoadjuvant chemoradiation alone\[[@B62]\]. Similarly, the ARTIST trial, which was designed to compare adjuvant chemotherapy to chemoradiation, failed to demonstrate a difference in disease-free and OS; however, subgroup analysis suggested that patients with intestinal type histology and lymph node metastasis, in particular, may benefit from chemoradiation\[[@B63]\]. A follow-up trial, ARTIST II, is currently under way addressing this question (NCT01761461). The TOPGEAR trial is another randomized prospective trial aimed at determining if pre-operative chemoradiation, in addition to perioperative chemotherapy, improves outcomes over perioperative chemotherapy alone\[[@B64]\].

The mode of radiation administration has traditionally been through three-dimensional conformal radiotherapy (3D-CRT). The potential advantage of using intensity-modulated radiotherapy (IMRT) over 3D-CRT is the ability to limit exposure to critical surrounding structures while delivering therapeutic doses to the organs of interest\[[@B65],[@B66]\]. One study found that overall and disease-free survival were significantly improved in patients treated with adjuvant IMRT compared to similar patients treated with adjuvant 3D-CRT\[[@B67]\]. There has been little investigation into the use of proton beam radiation for the treatment of locally advanced gastric cancer. Reasons for this include the limited availability of proton beam radiation in the United States and that a moderate dose of radiation over a large area may be ideal for treating the resection margins and wide nodal basin\[[@B68]\]. A benefit of proton beam radiation is its ability to provide a very high dose of radiation to a single lesion with relative sparing of adjacent structures, limiting damage to surrounding tissue\[[@B69]\]. Given these properties, there has been more interest in using proton beam radiation for unresectable primary liver tumors like hepatocellular carcinoma, or even gastric cancer hepatic metastases\[[@B69],[@B70]\]. For similar reason, stereotactic body radiotherapy (SBRT) has been under investigation for the treatment of liver tumors, though there has been a description of using SBRT for the treatment of lymph node recurrences after gastric resection\[[@B71],[@B72]\].

FUTURE DIRECTIONS
=================

While outcomes for patients with advanced gastric cancer have improved with medical and surgical advancement, there are still areas for improvement and exploration. The use of targeted treatments as adjuncts to traditional chemotherapeutic agents is under continued investigation (Table [4](#T4){ref-type="table"}). Epidermal growth factor receptor (EGFR) is overexpressed in most gastric cancers, however the trials that used anti-EGFR antibodies such as cetuximab (EXPAND Trial), and panitumumab (REAL3 Trial) failed to improve survival\[[@B8],[@B73]\]. In contrast, in the randomized phase III AVAGAST trial, bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), when given with cisplatin and a fluoropyrimidine was found to significantly improve progression-free survival in patients with unresectable or metastatic advanced gastric cancer though it did not improve OS (50% *vs* 42%)\[[@B74]\]. However, the use of ramucirumab, a VEGFR-2 inhibitor, in the REGARD trial was able to show a significant improvement in OS as a second-line option for patients with metastatic disease unresponsive to first-line therapy so there may be a role for its use in the perioperative setting in the future\[[@B75]\].

###### 

Targeted treatment trials

  **Trial name**                                                     **Country**                                          **Status**   **Years**   **Target**   **Groups**                                              **Chemotherapy regimens**               **Outcome**
  ------------------------------------------------------------------ ---------------------------------------------------- ------------ ----------- ------------ ------------------------------------------------------- --------------------------------------- -----------------------------------------------------------------------------
  EXPAND                                                             Multiple                                             Complete     2008-2010   EGFR         Standard chemo                                          Capecitabine, cisplatin                 No difference in PFS
  Standard chemo with cetuximab                                      Capecitabine, cisplatin, cetuximab                                                                                                                                                         
  REAL3                                                              Multiple                                             Complete     2008-2011   EGFR         Standard chemo                                          Epirubicin, oxaliplatin, capecitabine   No difference in OS
  Standard chemo with panitumumab                                    Epirubicin, oxaliplatin, capecitabine, panitumumab                                                                                                                                         
  AVAGAST                                                            Multiple                                             Complete     2007-2008   VEGFR        Standard chemo                                          Capecitabine, cisplatin                 Improved PFS in the bevacizumab group (median survival 6.7 mo *vs* 5.3 mo)
  Standard chemo with                                                Capecitabine, cisplatin,                                                                                                                                                                   
  bevacizumab                                                        bevacizumab                                                                                                                                                                                
  REGARD                                                             Multiple                                             Complete     2009-2012   VEGFR        Best supportive care                                    \-                                      Improved OS in ramucirumab group (median survival 5.2 mo *vs* 3.8 mo)
  Best supportive care                                               Ramucirumab                                                                                                                                                                                
  with ramucirumab                                                                                                                                                                                                                                              
  ToGA Trial                                                         Multiple                                             Complete     2005-2008   HER2         Standard chemo                                          Cisplatin with capecitabine or 5-FU     Improved OS in the trastuzumab group (median survival 13.8 mo *vs* 11.1 mo)
  Standard chemo with trastuzumab                                    Cisplatin, capecitabine or 5-FU, trastuzumab                                                                                                                                               
  KEYNOTE-012                                                        Multiple                                             Complete     2013-2014   PD-L1        Pembrolizumab                                           Pembrolizumab                           Median OS of 11.4 mo
  GASTRICHIP (NCT01882933)                                           Multiple                                             Ongoing      \-          HIPEC        Curative gastrectomy with D1-D2 lymph node dissection   \-                                      \-
  Curative gastrectomy with D1-D2 lymph node dissection with HIPEC   IP Oxaliplatin with IV 5-FU and leucovorin                                                                                                                                                 

EGFR: Endothelial growth factor receptor; chemo: Chemotherapy; PFS: Progression-free survival; OS: Overall survival; AVAGAST: Avastin in Gastric Cancer; VEGFR: Vascular endothelial growth factor receptor; ToGA: Trastuzumab for Gastric Cancer; HER2: Human epidermal growth factor receptor 2; 5-FU: 5-fluorouracil; PD-L1: Programmed death-ligand 1; HIPEC: Hyperthermic intraperitoneal chemotherapy; IP: Intraperitoneal; IV: Intravascular.

Another advance and future direction is using molecular analysis to better predict prognosis as well as treatment options for individual patients. One of these molecular characteristics is identification of patients with human epidermal growth factor receptor 2 (HER2) overexpression. Around 12%-24% of patients with gastric cancer have been found to have HER2 overexpression with most showing associated poorer outcomes when compared to patients with normal HER2 expression\[[@B76]-[@B78]\]. Intestinal type gastric cancers are much more likely to have overexpression than diffuse type (32% *vs* 6%)\[[@B79]\]. The randomized controlled ToGA trial found that in patients with HER2 overexpression, treatment with chemotherapy with trastuzumab was associated with improved OS when compared to patients treated with chemotherapy alone\[[@B79]\]. These results have led to NCCN guidelines recommending the assessment of HER2 expression and the addition of trastuzumab to all HER2 overexpressing metastatic gastric adenocarcinomas\[[@B32]\].

The use of pembrolizumab, a monoclonal antibody against programmed death 1 (PD-1), in patients with PD-L1-positive cancers is another example of how individualized treatment may impact specific patients based on their tumor's molecular characteristics. In a phase I study, pembrolizumab showed promising results as a single agent in patients with PD-L1-positive metastatic or recurrent gastric cancer that had failed other treatment regimens\[[@B80]\]. In this cohort, 22% of patients had a partial tumor response and the 1-year survival was 42%\[[@B80]\].

Additionally, there has been investigation into the adjuvant use of intraperitoneal chemotherapy. Peritoneal recurrence develops in about 60% of the patients with T3 and T4 tumors following curative-intent resection, and up to 40% of resected gastric cancer patients die as a direct result of peritoneal dissemination\[[@B13]\]. Few systemic chemotherapeutic agents penetrate the peritoneum well and intraperitoneal chemotherapy has less adverse effects with higher doses in the intraperitoneal regions than systemic chemotherapy\[[@B81]\]. A recent meta-analysis of 23 prospective randomized trials including 2767 advanced gastric patients from Japan, China, Korea, and Austria demonstrated that adjuvant intraperitoneal chemotherapy was associated with improved 1, 2 and 3-year survival rate, as well as a 30% reduction in the incidence of peritoneal recurrence\[[@B82]\]. Currently, the GASTRICHIP Trial, a randomized multicenter phase III clinical study, is evaluating the effects of hyperthermic intraperitoneal chemotherapy with oxaliplatin on patients with locally advanced gastric cancer and will hopefully provide further direction on the effectiveness of intraperitoneal chemotherapy for locally advanced gastric cancer\[[@B83]\].

CONCLUSION
==========

Treatment for advanced gastric cancer continues to evolve with better understanding of optimal treatment regimens, treatment sequences, and surgical optimization with improved technique. Additionally, future efforts in providing individualized treatment recommendations based on molecular characteristics at the time of the initial diagnosis have the opportunity to improve long-term outcomes.
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